We present a case of a severe reaction after anti-thymocyte administration despite premedication and strict adherence to administration guidelines during the conditioning regimen. Due to the severity of the adverse drug reaction, we believe that this case should be reported.
TheurichSFischmannHShimabukuro-VornhagenAet al.Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev2012; 9: CD009159–CD009159.
3.
SebeoJEzziddinOEisenkraftJB. Severe anaphylactoid reaction to thymoglobuline in a pediatric renal transplant recipient. J Clin Anesth2012; 24: 659–663.
4.
BevansMShalabiR. Management of patients receiving antithymocyte globulin for aplastic anemia and myelodysplastic syndrome. Clin J Oncol Nursing2004; 8: 377–382.
5.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03, www.cancer.gov (accessed 20 January 2015).
6.
NaranjoCABustoUSellersEMet al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
7.
ClemmonsABHartranftMEKotaVet al.Administration of anti-thymocyte globulin: a comparison of two protocols. Bone Marrow Transplant2014; 49: 1535–1537.
8.
FisherMMDoigGS. Prevention of anaphylactic reactions to anaesthetic drugs. Drug Saf2004; 27: 393–410.
